MedPath

Effects of Vildagliptin addition versus standard therapy on glycemic excursion in type2 diabetic patients after coronary intervention therapy: a 8-months, randomized, open-label, parallel-group comparison.

Not Applicable
Recruiting
Conditions
Type 2 diabetes mellitus
Registration Number
JPRN-UMIN000017619
Lead Sponsor
Teikyo University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

1) Exclusion criteria will comply with local label 2) Coronary bypass graft operation 3) Severe valvular heart disease 4) Severe arrhythmia (Extrasystole > 10% of total beats, atrial fibrillation, atrial flutter, pacemaker implantation, high grade heart block) 5) Congestive heart failure (NYHA III, IV) 6) Malignant neoplasms 7) Use of gluco-corticosteroids, immuno-suppressant 8) Serum Cr > 2.5 mg/dl 9) Cerebrovascular infarction or hemorrhage 10) Aneurysms in great artery 11) Liver cirrhosis 12) Recent (within 4 weeks) usage of incretin related drugs 13) Blood glucose > 400mg/dl or insulin usage 14) Recent change in diabetic treatment in one month 15) Use of Insulin, GLP-1 analogue, and OHAs excluding SU and metformin

Study & Design

Study Type
Interventional,observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Time spent in range 70-140 mg/dl
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath